Gelteq vs Incannex Healthcare
GELS and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GELS and IXHL compare
Incannex Healthcare scores higher on the StockData Score (7 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GELS | IXHL |
|---|---|---|
| Size and price | ||
| Market cap | – | $24.7M |
| Share price | $0.380 | $1.97 |
| Change, 1 year | −64.1% | −82.4% |
| Beta (5Y) | 2.50 | 1.95 |
| Employees | – | 12 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.4× |
| FCF yield | – | −52.1% |
| Profitability | ||
| Gross margin | 30.3% | – |
| Operating margin | −3318% | – |
| FCF margin | −3335% | – |
| Return on equity | – | −47.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −2.8× | – |
| Current ratio | 0.09 | 48.81 (better) |
| Altman Z-score | – | −0.62 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −280% |
| Shareholder yield | – | −280% |
| Ownership | ||
| Held by institutions | – | 3.6% |
| Held by insiders | 14.0% | – |
Go deeper
- GELS stock overview
- GELS income statement
- GELS valuation and score
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.